A Follow-up Study to Evaluate the Safety of RetinoStat® in Patients With Age-Related Macular Degeneration

NCT01678872 · tracked via the Priya Life Science USA tracker

Sponsor

Oxford BioMedica

Phase

Phase 1

Started

2012-08

Last updated

2026-01-14

Condition(s) studied

Age-Related Macular Degeneration

Investigational drug(s) / intervention(s)

RetinoStat

RetinoStat: Long Term Follow up of patients who received RetinoStat in a previous study

Study summary

The purpose of this study is to examine the long term safety of an experimental gene transfer agent, RetinoStat®, designed to treat neovascular age-related macular degeneration.

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Must have received a subretinal injection of RetinoStat * Must have been enrolled in Protocol RS1/001/10 Exclusion Criteria: * Did not receive RetinoStat® as part of the RS1/001/10 protocol

Primary outcome measure(s)

The incidence of adverse events — 14 years
The number of subjects with treatment emergent adverse events.

Trial sites (3)

Facility	City	Region
University of Iowa Hospitals & Clinics	Iowa City	Iowa
John Hopkins University Hospital	Baltimore	Maryland
Oregon Health & Science University	Portland	Oregon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01678872 on ClinicalTrials.gov ↗ ← All trials in the USA